Latest from Mayo Clinic Cancer Center

Mitesh J. Borad, MD, associate professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, discusses the results of the SARAH and SIRveNIB studies in patients with hepatocellular carcinoma.
Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses the role of immunotherapy in treating patients with gastric/gastroesophageal cancers.
Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses treatment options for patients with relapsed/refractory multiple myeloma.
 
Keith Stewart, MB, ChB, discusses the role of stem cell transplant, minimal residual disease testing, and maintenance therapy in the treatment of patients with multiple myeloma.
Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses competing strategies in treating patients with relapsed multiple myeloma.
Tanios Bekaii-Saab, MD, sheds light on the recent advances in the treatment of patients with hepatocellular carcinoma. 
Rafael Fonseca, MD, discusses the integration of biology and treatment selection for patients with newly diagnosed multiple myeloma.
Jeanne M. Palmer, MD, discusses the current treatment landscape for patients with polycythemia vera and highlighted the impact that ruxolitinib has had on the second-line treatment setting.
Publication Bottom Border
Border Publication
x